KHẢO SÁT ĐẶC ĐIỂM LÂM SÀNG, SINH HỌC VÀ KẾT QUẢ ĐIỀU TRỊ PHÁC ĐỒ CÓ RITUXIMAB TRÊN NGƯỜI BỆNH U LYMPHO VÙNG RÌA NGOÀI HẠCH LIÊN QUAN ĐẾN NIÊM MẠC

Background: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALTL) is the most common subtype of marginal zone lymphoma, typically associated with chronic inflammation or persistent infection and generally conferring a favorable prognosis. In advanced disease or disease not amenable to local therapy, rituximab-based regimens provide high treatment efficacy. In Vietnam, data on MALTL remain limited.Objective: To describe the clinical and biological characteristics and evaluate treatment outcomes of rituximab-based regimens in patients with MALTL.Subjects and methods: A retrospective case series was conducted on 31 patients with MALTL treated with rituximab-based regimens at Cho Ray Hospital and the Blood Transfusion and Hematology Hospital from January 2018 to December 2024.Results: Thirty-one patients were included; mean age was 55.2 ± 10.3 years, and 67.7% were male. The stomach was the most common site of involvement (41.9%). Anemia was observed in 32.3%, elevated LDH in 22.6%, and bone marrow involvement in 25.8%. The low–intermediate IPI risk group accounted for the highest proportion (38.7%). The most frequently used regimens were R-CHOP (48.4%) and R-B (32.3%). The complete response rate increased from 64.3% at mid-treatment to 77.4% at end-of-treatment, with an overall response rate of 90.3%. After a median follow-up of 22 months, the 2-year and 4-year overall survival rates were 96% and 78.2%, respectively; 2-year and 4-year progression-free survival rates were 85.9% and 68.3%. Three deaths and one late relapse were documented.Conclusion: Rituximab-based regimens demonstrated high efficacy and favorable survival outcomes in patients with MALTL, providing initial real-world data for clinical practice in Vietnam.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine Bach Mai Hospital
Published
2026-11-21
DOI
https://doi.org/10.52322/jocmbmh.156.0313
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

KHẢO SÁT ĐẶC ĐIỂM LÂM SÀNG, SINH HỌC VÀ KẾT QUẢ ĐIỀU TRỊ PHÁC ĐỒ CÓ RITUXIMAB TRÊN NGƯỜI BỆNH U LYMPHO VÙNG RÌA NGOÀI HẠCH LIÊN QUAN ĐẾN NIÊM MẠC

Gia Khánh Đinh, Thị Xinh Phan, Trinh Thuy Duong, Thanh Tùng Trần et al.
Journal of Clinical Medicine Bach Mai Hospital
Lymphoma Diagnosis and Treatment
article

KHẢO SÁT ĐẶC ĐIỂM LÂM SÀNG, SINH HỌC VÀ KẾT QUẢ ĐIỀU TRỊ PHÁC ĐỒ CÓ RITUXIMAB TRÊN NGƯỜI BỆNH U LYMPHO VÙNG RÌA NGOÀI HẠCH LIÊN QUAN ĐẾN NIÊM MẠC

Gia Khánh Đinh, Thị Xinh Phan, Trinh Thuy Duong, Thanh Tùng Trần, Thị Tuyết Nhung Phạm, Nghĩa Huỳnh
article en

Abstract

Background: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALTL) is the most common subtype of marginal zone lymphoma, typically associated with chronic inflammation or persistent infection and generally conferring a favorable prognosis. In advanced disease or disease not amenable to local therapy, rituximab-based regimens provide high treatment efficacy. In Vietnam, data on MALTL remain limited.Objective: To describe the clinical and biological characteristics and evaluate treatment outcomes of rituximab-based regimens in patients with MALTL.Subjects and methods: A retrospective case series was conducted on 31 patients with MALTL treated with rituximab-based regimens at Cho Ray Hospital and the Blood Transfusion and Hematology Hospital from January 2018 to December 2024.Results: Thirty-one patients were included; mean age was 55.2 ± 10.3 years, and 67.7% were male. The stomach was the most common site of involvement (41.9%). Anemia was observed in 32.3%, elevated LDH in 22.6%, and bone marrow involvement in 25.8%. The low–intermediate IPI risk group accounted for the highest proportion (38.7%). The most frequently used regimens were R-CHOP (48.4%) and R-B (32.3%). The complete response rate increased from 64.3% at mid-treatment to 77.4% at end-of-treatment, with an overall response rate of 90.3%. After a median follow-up of 22 months, the 2-year and 4-year overall survival rates were 96% and 78.2%, respectively; 2-year and 4-year progression-free survival rates were 85.9% and 68.3%. Three deaths and one late relapse were documented.Conclusion: Rituximab-based regimens demonstrated high efficacy and favorable survival outcomes in patients with MALTL, providing initial real-world data for clinical practice in Vietnam.

Journal of Clinical Medicine Bach Mai HospitalVol. 3(156)
Cho Ray Hospital (VN)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
KHẢO SÁT ĐẶC ĐIỂM LÂM SÀNG, SINH HỌC VÀ KẾT QUẢ ĐIỀU TRỊ PHÁC ĐỒ CÓ RITUXIMAB TRÊN NGƯỜI BỆNH U LYMPHO VÙNG RÌA NGOÀI HẠCH LIÊN QUAN ĐẾN NIÊM MẠC — Gia Khánh Đinh, Thị Xinh Phan, et al. · Journal of Clinical Medicine Bach Mai Hospital (2026) | TGRS Research Map | TGRS